公开(公告)号：US12083101B2

公开(公告)日：2024-09-10

申请号：US17201268

申请日：2021-03-15

Applicant: Novartis AG

Inventor： Vincent Bordas ,  Cara Brocklehurst ,  Patrick Chene ,  Pascal Furet ,  Vito Guagnano ,  Patricia Imbach-Weese ,  Joerg Kallen ,  Mickael Le Douget ,  Edwige Liliane Jeanne Lorthiois ,  Joseph McKenna ,  Bahaa Salem ,  Tobias Schmelzle ,  Holger Sellner ,  Nicolas Soldermann ,  Markus Voegtle ,  Markus Wartmann

IPC: A61K31/4155 ,  A61K31/343 ,  A61K31/351 ,  A61K31/357 ,  A61K31/4025 ,  A61K31/403 ,  A61K31/404 ,  A61K31/41 ,  A61K31/426 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/4525 ,  A61K31/506 ,  A61P35/00 ,  C07D307/81 ,  C07D401/14 ,  C07D403/04 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D407/04 ,  C07D407/12 ,  C07D413/04 ,  C07D417/04 ,  C07D491/04

CPC classification number: A61K31/4155 ,  A61K31/343 ,  A61K31/351 ,  A61K31/357 ,  A61K31/4025 ,  A61K31/403 ,  A61K31/41 ,  A61K31/426 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/4525 ,  A61K31/506 ,  A61P35/00 ,  C07D307/81 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D407/04 ,  C07D407/12 ,  C07D417/04

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof;






a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

公开(公告)号：US11530413B2

公开(公告)日：2022-12-20

申请号：US16632777

申请日：2018-07-20

Applicant: NOVARTIS AG

Inventor： Eric Billy ,  Antoine De Weck ,  Javad Golji ,  Gregory Hoffman ,  Francesco Hofmann ,  Audrey Kauffmann ,  Konstantinos John Mavrakis ,  Earl Robert McDonald, III ,  William Sellers ,  Tobias Schmelzle ,  Frank Peter Stegmeier ,  Michael Ray Schlabach, Jr.

IPC: C12N15/115 ,  A61K45/06 ,  C12N9/22 ,  C12N15/113 ,  G01N33/574 ,  A61K47/18

Abstract: The disclosure provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating patients having cancer, wherein the cancer is amenable to therapeutic treatment with an inhibitor, e.g., an inhibitor of any of the targets disclosed herein. Kits, methods of screening for candidate inhibitors, and associated methods of treatment are also provided.